Bedaquiline for MDR Tuberculosis – The FDA advisory committee

It is not always easy to conclude on the B/R after assessment of the available data on quality, safety, and efficacy of medical products. Therefore, regulatory authorities make such decisions by working together with experts in the field; in some cases, even the public and special interest groups can have the opportunity to provide input during an open hearing.